App-Quantinova.ai

Correlation among the biomarkers for oral anti-cancer agents in lung adenocarcinoma.

Nariyasu Nakashima - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

EGFR mutations in tumor tissue and blood collected from lung cancer patients by Insight Onco NGS technique.

Jin-Hyoung Kang - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Outcomes in patients with stage III non-small cell lung cancer (NSCLC) treated with cisplatin and irinotecan with concurrent thoracic radiotherapy (CRT): A multi-disciplinary thoracic oncology experience at East Carolina University.

Jessica R. Hildebrand - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

cisplatin + irinotecan

Normal-lung uptake of fluorodeoxyglucose, patient-reported symptoms, and clinician-rated radiation pneumonitis in patients with non-small cell lung cancer treated with chemoradiation. - Publication Only: Lung CancerNon-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

Jinbo Yue - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Unusual pattern of KRAS mutations in inner city patients with NSCLC.

Yuanquan Yang - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Role in carcinogenesis and clinical significance of Merkel cell polyomavirus in non-small cell lung cancer.

Deok Heon Lee - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Pulmonary sarcomatoid carcinoma (PSC): A 40 year experience at a comprehensive cancer center.

Priyank P. Patel - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Predictive value of the early response in locally advanced nonsmall cell lung cancer treated with concurrent chemoradiotherapy by 18F-alfatide RGD PET/CT.

Song Gao - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Correlation of FDG PET/CT heterogeneity with disease recurrence in early-stage, non-small cell lung cancer.

Justin David Blasberg - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Pulmonary Sarcomatoid Carcinoma with ALK rearrangement: Frequency, Clinical-Pathological Characteristics, and Response to ALK inhibitor.

Xinru Chen - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Crizotinib

Predictors of atrial fibrillation and inpatient mortality in post lobectomy lung cancer patients.

Supreet Kaur - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Metformin effect on clinical course of non-small cell lung cancer (NSCLC) in patients (pts.) with concomitant diabetes mellitus (DM) after radical resection.

Igor A. Leyman - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Metformin Hydrochloride

Icotinib and rh-endostatin as first line therapy in advanced non small cell line cancer patients harboring activating epidermal growth factor receptor mutations.

Qiong Zhao - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Recombinant human endostatin

Patient-reported outcomes (PROs) in the double-blind phase 3 trial (NGR015) with NGR-hTNF plus best investigator choice (BIC) versus placebo plus BIC for previously treated patients with malignant pleural mesothelioma (MPM).

Vanesa Gregorc - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

NGR-hTNF

Loss of somatostatin receptor 2 expression and cellular metabolism and survival in small cell lung cancer.

Jonathan Lehman - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Somatostatin

Evaluation of anti-cancer stem cell activity of the anti-DLL4 antibody MEDI0639 in a phase I clinical trial of SCLC.

Haifeng Bao - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

MEDI 0639

Risk factors for brain metastases after prophylactic cranial irradiation in small cell lung cancer.

Haiyan Zeng - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Functional imaging as a tool in individualized treatment in advanced thymic epithelial tumors.

Giovannella Palmieri - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Capecitabine

Expression of PD-L1, PD-L2 and PD-1 in thymic epithelial tumours (TETs).

Spyridon Gennatas - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Integrated digital error suppression for noninvasive detection of circulating tumor DNA in NSCLC.

Aaron M. Newman - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

IdeS

Filters

41730 Abstracts